SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla launches authorized generic of Aloxi

26 Mar 2018 Evaluate

Cipla USA, (Cipla) has launched an authorized generic version of Aloxi in the United States under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva.

Helsinn Healthcare SA currently manufactures and markets Aloxi in the United States through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics (US) Inc. Aloxi containing palonosetron hydrochloride injections (Eq. 0.25 mg base/5 ml) is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and for prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

According to IMS Health, Aloxi brand had US sales of approximately $460 million for the 12-month period ending November 2017. Cipla’s Authorized Generic of Aloxi is available for shipping immediately.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1294.75 -11.10 (-0.85%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×